Amer Sports, the company behind Wilson sporting goods and Arc’teryx clothing is looking to raise $1.8 billion in an initial public offering. The company is seeing to issue 100 million shares at a price of $16 to $18 per share, according to regulatory filings. It would give the company a valuation of up to $8.7 billion. Yahoo Finance's Brad Smith and Seana Smith discuss the filing. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live. Editor's note: This article was written by Stephanie Mikulich
Amer Sports, the company behind Wilson sporting goods and Arc’teryx clothing is looking to raise $1.8 billion in an initial public offering. The company is seeing to issue 100 million shares at a price of $16 to $18 per share, according to regulatory filings. It would give the company a valuation of up to $8.7 billion.
Yahoo Finance's Brad Smith and Seana Smith discuss the filing.
For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live.
Editor's note: This article was written by Stephanie Mikulich
Barrons.com
The S&P 500 was creeping up on Monday to mark a set of consecutive record closes. The S&P 500, up 0.4%, was on pace for another all-time high, a first twofold boon since December 2021. After a pair of consecutive record closes, the S&P 500 has historically averaged a gain of 3.9% in the following six months going back all the way to 1950, according to Dow Jones Market Data.
Bloomberg
(Bloomberg) -- US regulators’ latest attempt to make the Federal Reserve’s discount window part of banks’ everyday liquidity plans could end the tool’s decades-old stigma, according to JPMorgan Chase & Co. Most Read from BloombergFlorida Governor DeSantis Drops Out of 2024 Race, Endorses TrumpHong Kong Stocks at 36% Discount Show True Depth of China GloomMorgan Stanley, JPMorgan Say Buy the Dip After Treasury RoutGloom Over China Assets Is Spreading Beyond Battered StocksHedge Funds Rake in Huge
The Wall Street Journal
American depositary receipts in major Chinese companies sold off, [echoing the latest declines for markets in Hong Kong and mainland China](https://www.wsj.com/livecoverage/stock-market-today-dow-jones-01-22-2024/card/breaking-down-china-s-brutal-stock-selloff-ZFEEDeLDVifaSLukNpZk).
Bloomberg
(Bloomberg) -- Gilead Sciences Inc.’s Trodelvy failed to significantly improve survival in a trial of patients with advanced lung cancer, a blow to the targeted treatment that’s in one of the most promising classes in oncology.Most Read from BloombergFlorida Governor DeSantis Drops Out of 2024 Race, Endorses TrumpHong Kong Stocks at 36% Discount Show True Depth of China GloomMorgan Stanley, JPMorgan Say Buy the Dip After Treasury RoutGloom Over China Assets Is Spreading Beyond Battered StocksHed
Read more --->